Sugi Predict

Sugi Predict / Compounds / SCHEMBL400256

SCHEMBL400256

SCHEMBL400256

CN1CCN(C2CC(C3=C4C=NC=C[N+]4(N)C(c4ccc5ccc(-c6ccccc6)nc5c4)=N3)C2)CC1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ IGF1R P08069 17/20 0.49
▸ CYP3A4 P08684 6/20 0.49
▸ INSR P06213 5/20 0.49
▸ MAPK3 P27361 2/20 0.49
▸ MAPK1 P28482 2/20 0.49
▸ MAPK6 Q16659 1/20 0.49
▸ KDM4E B2RXH2 2/20 0.37
▸ NPC1 O15118 1/20 0.37
▸ MAPT P10636 1/20 0.37
▸ XBP1 P17861 1/20 0.37
▸ RAB9A P51151 1/20 0.37
▸ KLF5 Q13887 1/20 0.37
▸ SMN1; SMN2 Q16637 1/20 0.37
▸ TNK2 Q07912 1/20 0.33
▸ GLA P06280 1/20 0.33
▸ HTT P42858 1/20 0.33
▸ RIPK2 O43353 1/20 0.33
▸ ROCK2 O75116 1/20 0.33
▸ LATS1 O95835 1/20 0.33
▸ LCK P06239 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL401941 0.93 IGF1R (0.47) IGF1RCYP3A4INSRMAPK3MAPK1
SCHEMBL402576 0.92 IGF1R (0.47) IGF1RCYP3A4INSRMAPK3MAPK1
SCHEMBL400414 0.91 IGF1R (0.40) IGF1RCYP3A4INSRMAPK3MAPK1
SCHEMBL398126 0.90 IGF1R (0.49) IGF1RCYP3A4INSRMAPK3MAPK1
SCHEMBL1567001 0.90 IGF1R (0.49) IGF1RCYP3A4INSRMAPK3MAPK1
SCHEMBL398423 0.90 IGF1R (0.40) IGF1RCYP3A4INSRMAPK3MAPK1
SCHEMBL397601 0.90 IGF1R (0.42) IGF1RCYP3A4INSRMAPK3MAPK1
SCHEMBL400068 0.90 IGF1R (0.45) IGF1RCYP3A4INSRMAPK3MAPK1
SCHEMBL402773 0.90 IGF1R (0.40) IGF1RCYP3A4INSRMAPK3MAPK1
SCHEMBL868025 0.90 IGF1R (0.40) IGF1RCYP3A4INSRMAPK3MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2168968-B1 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors OSI PHARMACEUTICALS LLC (US) 2017-08-23 — — EP disclosed
US-8735405-B2 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors OSI Pharmaceuticals, LLC (US) 2014-05-27 — — US disclosed
US-8653268-B2 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors OSI Pharmaceuticals, LLC (US) 2014-02-18 — — US disclosed
US-8575164-B2 Combination cancer therapy OSI Pharmaceuticals, LLC (US) 2013-11-05 — — US disclosed
US-20130190496-A1 6,6-Bicyclic Ring Substituted Heterobicyclic Protein Kinase Inhibitors OSI Pharmaceuticals, LLC 2013-07-25 — — US disclosed
US-8367826-B2 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors OSI Pharmaceuticals, LLC (US) 2013-02-05 — — US disclosed
US-20120214830-A1 BIOLOGICAL MARKERS PREDICTIVE OF ANTI-CANCER RESPONSE TO INSULIN-LIKE GROWTH FACTOR-1 RECEPTOR KINASE INHIBITORS IN HEPATOCELLULAR CARCINOMA OSI Pharmaceuticals, LLC 2012-08-23 — — US disclosed
US-20120201832-A1 BIOLOGICAL MARKERS PREDICTIVE OF ANTI-CANCER RESPONSE TO INSULIN-LIKE GROWTH FACTOR-1 RECEPTOR KINASE INHIBITORS THE REGENTS OF THE UNIVERSITY OF COLORADO (US) 2012-08-09 — — US disclosed
US-20120196847-A1 6,6-Bicyclic Ring Substituted Heterobicyclic Protein Kinase Inhibitors OSI Pharmaceuticals, LLC 2012-08-02 — — US disclosed
US-8178091-B2 Compositions and methods for the treatment of respiratory disorders UNIVERSITY OF WASHINGTON (US) 2012-05-15 — — US disclosed
US-20080299113-A1 Combined treatment with and composition of 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitor and anti-cancer agents OSI PHARMACEUTICALS, INC. 2008-12-04 — — US disclosed
WO-2008144720-A2 INHIBITORS OF IGF-1R SIGNALING FOR THE TREATMENT OF RESPIRATORY DISORDERS UNIVERSITY OF WASHINGTON (US) 2008-11-27 — — WO disclosed
US-20080267957-A1 Combination cancer therapy OSI PHARMACEUTICALS, INC. 2008-10-30 — — US disclosed
EP-1979002-A2 COMBINATION OF IGFR INHIBITOR AND ANTI-CANCER AGENT OSI Pharmaceuticals, Inc. (US) 2008-10-15 — — EP disclosed
WO-2008076143-A1 COMBINATION OF IGFR INHIBITOR AND ANTI-CANCER AGENT OSI PHARMACEUTICALS, INC. (US) 2008-06-26 — — WO disclosed
US-20080014200-A1 Combined treatment with 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitor and anti-cancer agents OSI PHARMACEUTICALS, INC. 2008-01-17 — — US disclosed
WO-2007075554-A2 COMBINATION OF IGFR INHIBITOR AND ANTI-CANCER AGENT OSI PHARMACEUTICALS, INC. (US) 2007-07-05 — — WO disclosed
EP-1740591-A1 6,6-BICYCLIC RING SUBSTITUTED HETEROBICYCLIC PROTEIN KINASE INHIBITORS OSI Pharmaceuticals, Inc. (US) 2007-01-10 — — EP disclosed
US-20060235031-A1 6,6-Bicyclic ring substituted heterobicyclic protein kinase inhibitors ACERTA PHARMA B.V. (NL) 2006-10-19 — — US disclosed
WO-2005097800-A1 6,6-BICYCLIC RING SUBSTITUTED HETEROBICYCLIC PROTEIN KINASE INHIBITORS OSI PHARMACEUTICALS, INC. (US) 2005-10-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120201832-A1 BIOLOGICAL MARKERS PREDICTIVE OF ANTI-CANCER RESPONSE TO INSULIN-LIKE GROWTH FACTOR-1 RECEPTOR KINASE INHIBITORS IGF1R, IGFBP1, IGFBP2 IGF1R 1/4885CYP3A4 4803/4885INSR 11/4885
US-20130190496-A1 6,6-Bicyclic Ring Substituted Heterobicyclic Protein Kinase Inhibitors IGF1R, MAP2K7, BRCA1 IGF1R 1/4885CYP3A4 1815/4885INSR 27/4885
US-20080014200-A1 Combined treatment with 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitor and anti-cancer agents IGF1R, IGFBP6, CDK6 IGF1R 1/4885CYP3A4 2272/4885INSR 104/4885
US-20120214830-A1 BIOLOGICAL MARKERS PREDICTIVE OF ANTI-CANCER RESPONSE TO INSULIN-LIKE GROWTH FACTOR-1 RECEPTOR KINASE INHIBITORS IN HEPATOCELLULAR CARCINOMA IGFBP1, IGFBP3, IGFBP2 IGF1R 6/4885CYP3A4 3065/4885INSR 26/4885
US-20080299113-A1 Combined treatment with and composition of 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitor and anti-cancer agents IGF1R, EGFR, ERBB2 IGF1R 1/4885CYP3A4 2312/4885INSR 62/4885
US-20120196847-A1 6,6-Bicyclic Ring Substituted Heterobicyclic Protein Kinase Inhibitors IGF1R, MAP2K7, BRCA1 IGF1R 1/4885CYP3A4 1815/4885INSR 27/4885
US-20080267957-A1 Combination cancer therapy IGF1R, IGFBP4, IGFBP1 IGF1R 1/4885CYP3A4 1844/4885INSR 10/4885
US-20060235031-A1 6,6-Bicyclic ring substituted heterobicyclic protein kinase inhibitors IGF1R, MAP2K7, BRCA1 IGF1R 1/4885CYP3A4 1815/4885INSR 27/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.